• Molecular NameFosamprenavir
  • SynonymNA
  • Weight585.615
  • Drugbank_IDDB01319
  • ACS_NO226700-81-8
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)0.95
  • pkaN/A
  • LogD (pH=7, predicted)-3.87
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.71
  • LogSw (predicted, AB/LogsW2.0)0.05
  • Sw (mg/ml) (predicted, ACD/Labs)0.15
  • No.of HBond Donors5
  • No.of HBond Acceptors12
  • No.of Rotatable Bonds14
  • TPSA195.91
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA pro-drug of the protease inhibitor and antiretroviral drug amprenavir.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding90.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHydrolysed to amprenavir and phosphate in GI tract epithelium
  • Half life7.7 h
  • ExcretionFecal (as metabolites of amprenavir)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A